KAISER FOUNDATION HEALTH PLAN INC. for KAISER FOUNDATION HEALTH PLAN INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 18, 2019 | $160,000 | Replaced |
| 3rd Quarter - Amendment | Jan 23, 2020 | $180,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
Legislation and regulation regarding the TRICARE program
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID C BENNETT | — |
| FISH BROWN | — |
| LAIRD D BURNETT | — |
| MARY PRUDENCE FITZPATRICK | — |
Taxation/Internal Revenue Code TAX
S. 6748, regarding the Cadillac tax HR 2447, to repeal the health insurance tax contained in the ACA HR 748, Regarding the Cadillac tax on high cost employer provided health coverage. S. 80, to repeal the ACA health insurance tax. S. 172, to suspend for two years the ACA health insurance tax. HR 1398, to suspend the ACA health insurance tax for two years. S. 73, regarding the tax deduction for direct-to-consumer advertising
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID C BENNETT | — |
| FISH BROWN | — |
| LAIRD D BURNETT | — |
| MARY PRUDENCE FITZPATRICK | — |
Health Issues HCR
HR 2328, PCORI Reauthorization HR 2328, the No Surprises Act S. 1895, the Lower Health Care Costs Act HR 987 and S. 455, regarding outreach and education activities under the ACA HR 3439, regarding the reauthorization of PCORI House Resolution 271, regarding the Justice Departments position in Texas v. United States HR 2062 & S. 1012, regarding 42 CFR Part 2 and confidentiality of certain health information HR 1884, with provisions to stabilize and strengthen the ACA and the nongroup insurance market. S. 470, regarding a Medicare buy-in option for individuals aged 50-64 S. 489 and HR 1277, regarding a Medicaid buy-in option S. 1129, to establish a single payer system based on Medicare for All. HR 1384, to establish a single payer health care system HR 1425, regarding reinsurance funding under the ACA HR 986 and S. 466, regarding Section 1332 state waiver guidance. HR 1010, regarding Short Term Limited Duration Insurance policies HR 1143, regarding Short Term Limited Duration Insurance policies HR 861, regarding surprise billing
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID C BENNETT | — |
| FISH BROWN | — |
| LAIRD D BURNETT | — |
| MARY PRUDENCE FITZPATRICK | — |
Medicare/Medicaid MMM
HR 4378, Continuing Appropriations and Health Extenders Act HR 1839, the Medicaid Services Investment and Accountability Act HR 3253, The Empowering Beneficiaries, Ensuring Access and Strengthening Accountability Act (regarding Medicaid) HR 2131 and S. 1114, regarding the Medicare Advantage benchmark cap HR 3107, regarding the use of preauthorization in the Medicare Advantage program HR 3417 the Beneficiary Education Tools, Telehealth and Extenders Reauthorization Act (regarding Medicare) Legislation and regulation regarding the Medicare Advantage program HR 1839, regarding multiple Medicaid program changes, including the Medicaid Drug Rebate program. HR 2131 and S. 1114, to remove the Medicare benchmark cap. HR 1046 and S. 377, regarding Medicare Part D and requirements for HHS to negotiate drug prices HR 1781 Regarding MedPAC and MACPAC access to drug pricing and rebate data.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID C BENNETT | — |
| FISH BROWN | — |
| LAIRD D BURNETT | — |
| MARY PRUDENCE FITZPATRICK | — |
Pharmacy PHA
S. 2543, Prescription Drug Pricing Reduction Act HR 2296, regarding prescription drug pricing HR 3, regarding prescription drug pricing (Pelosi) HR 4455, regarding Biologics in Medicare Part D S. 6748, regarding the Cadillac tax HR 4378, Continuing Appropriations and Health Extenders Act S. 2543, Prescription Drug Pricing Reduction Act HR 1781, regarding access to data for MedPAC and MACPAC HR 2113, regarding drug price transparency HR 2374, regarding generic drugs and citizens petitions HR 2375, regarding pay for delay agreements and generic drugs HR 2376, regarding the Federal Trade Commissions role in assuring competition in the pharmaceutical supply chain HR 2064, regarding reporting of prescription drug samples given to physicians by manufacturers HR 478 and S. 61, regarding drug reimportation HR 965 and S 340, regarding abuse of Risk Evaluation and Mitigation Strategies (REMS) (CREATES Act) HR 1499, regarding pay for delay in pharmaceutical markets HR 1503, regarding the FDA Orange Book HR 1520, regarding the FDA Purple Book HR 938, regarding generic drug approvals HR 2113, regarding drug pricing transparency
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID C BENNETT | — |
| FISH BROWN | — |
| LAIRD D BURNETT | — |
| MARY PRUDENCE FITZPATRICK | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.